Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition containing telmisartan and pitavastatin

A technology of telmisartan and pitavastatin, which is applied in the field of joint application of antihypertensive and lipid-lowering drugs, can solve the problems of reducing the sensitivity of antihypertensive drugs and increasing the difficulty of clinical antihypertensive treatment, and achieves the protection of endothelial cells and antihypertensive drugs. Effects of oxidation, low potential for drug interaction, and low incidence of side effects

Active Publication Date: 2013-06-12
SICHUAN UNIV
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Patients with hypertension are usually accompanied by dyslipidemia. Hyperlipidemia can also reduce the sensitivity of antihypertensive drugs and increase the difficulty of clinical antihypertensive treatment; dyslipidemia can easily lead to hypertension

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing telmisartan and pitavastatin
  • Medicinal composition containing telmisartan and pitavastatin
  • Medicinal composition containing telmisartan and pitavastatin

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0057] Experimental Example 1: Blood Pressure and Lipid Lowering Experiment

[0058] 1. Experimental animals:

[0059] Spontaneously hypertensive rats (SHR), raised at SPF level, male, aged 11 weeks.

[0060] WHY rats, SPF grade, male, 8 weeks old.

[0061] 2. Experimental grouping

[0062] Take 10 WHY male rats as the vehicle control group, and 90 SHR male rats were randomly divided into 9 groups according to blood pressure. The specific groups and dosages are shown in Table 1:

[0063] Table 1: Grouping, animal sex, quantity and dosage

[0064] group

gender

quantity

Dose (mg / kg)

Vehicle control group

the male

10

Equal volume of solvent

Model control group

the male

10

Equal volume of solvent

Group 0 (telmisartan / pitavastatin calcium)

the male

10

3.6mg / kg+0.18mg / kg

Group 1 (telmisartan sodium salt / pitavastatin calcium salt)

the male

10

3.6mg / kg+0.18mg / kg

Group 2 (telmis...

experiment example 2

[0092] Experimental Example 2: Optimal Experiment of the Dosage Range of the Combination of Telmisartan and Pitavastatin Calcium

[0093] Taking Telmisartan and Pitavastatin Calcium as an example, the dose ratio was tested. The experimental methods and results are as follows:

[0094] 1. Experimental animals: the same as Experimental Example 1.

[0095] 2. Experimental grouping

[0096] 10 healthy WKY rats were taken as the vehicle control group, and 110 SHR rats were randomly divided into 11 groups according to blood pressure, of which groups 1-10 were composed of telmisartan and pitavastatin calcium according to different ratios. For specific groups, see Table 4:

[0097] Table 4: Grouping, animal sex, quantity and dosage

[0098]

[0099] Note: The human dose is converted based on the rat dose through the body surface area

[0100] 3. Experimental method: same as experimental example 1.

[0101] 4. Detection index: same as Experiment 1.

[0102] 5. Statistical meth...

experiment example 3

[0128] Experimental Example 3: Study on the Synergistic Protective Effect on Cardiovascular System and Kidney

[0129] Taking telmisartan and pitavastatin calcium as an example, the effect experiment on cardiovascular effects was carried out. The experimental methods and results are as follows:

[0130] 1. Experimental animals: same as Experimental Example 1;

[0131] 2. Experimental grouping and methods:

[0132] Experimental group:

[0133] Ten healthy WKY male rats were taken as the vehicle control group, and 40 SHR male rats were randomly divided into 4 groups according to blood pressure. The specific groups are shown in Table 7:

[0134] Table 7: Grouping, animal sex, quantity and dosage

[0135] group

gender

quantity

Dose (mg / kg)

Vehicle control group

the male

10

-

[0136] Model control group

the male

10

-

Telmisartan group

the male

10

3.6

pitavastatin calcium group

t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicinal composition containing pitavastatin and telmisartan. The medicinal composition contains pitavastatin or a salt thereof, and telmisartan or a salt thereof. The medicinal composition has a synergistic effect in the field of the treatment of hyperlipidemia and hypertension, and is better than medicines in the prior art.

Description

technical field [0001] The invention belongs to the field of combined application of blood pressure-lowering and blood-lipid-lowering drugs, in particular to a pharmaceutical composition containing telmisartan and pitavastatin. Background technique [0002] Pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, can reduce the synthesis of mevalonate, thereby reducing the amount of cholesterol synthesis. Pitavastatin mainly acts on the liver, inhibits the synthesis of cholesterol in the liver, reduces the concentration of cholesterol in liver cells, promotes the concentration-dependent increase in the density and activity of low-density lipoprotein (LDL) receptors, accelerates the catabolism of LDL, and can reduce the concentration of low-density lipoprotein (LDL) receptors. The synthesis of high-density lipoprotein (VLDL) reduces the conversion of VLDL into LDL, thereby reducing the level of plasma low-density lipoprotein cholesterol (LDL-C). P...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4709A61K31/4184A61P3/06A61P9/12
Inventor 宋相容魏于全
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com